Acute myeloid leukemia (AML) with 11q23/rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on thefusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (allo...
作者发现FOXM1上调可激活WNT/β-catenin信号通路,与β-catenin结合,抑制β-catenin的降解,从而促进MLL-r AML(在婴儿中发生率占70%,在AML中占10%)LSC的自我更新。且MLL-AF9 AML病人的LSC对FOXM1抑制剂敏感,而正常的造血干细胞HSC对FOXM1抑制剂...
而lncrna在白血病中的重要调控作用逐渐被发掘,在急性淋巴细胞白血病(acutelymphoblasticleukemia,all)和急性髓细胞性白血病(acutemyeloidleukemia,aml)中,lncrna都具有特异的表达模式,提示lncrna在不同分型的白血病中都存在重要的调控作用。因此,针对mll-r白血病的治疗靶点具有重要的理论和应用意义,而且也能为lncrna在其他白...
Acute myeloid leukemia (AML) remains difficult to treat and requires new therapeutic approaches. Potent inhibitors of the chromatin-associated protein MENIN have recently entered human clinical trials, opening new therapeutic opportunities for some genetic subtypes of this disease. Using genome-scale funct...
Whereas CD19neg relapse has been observed across a broad spectrum of B-ALL patients treated with CD19-directed therapy, patients with MLL-r have manifested the emergence of AML, often clonally related to the B-ALL, suggesting that the inherent heterogeneity or lineage plasticity of MLL-r B-...
【用于急性髓系白血病!突破性小分子疗法达到临床主要终点】北京时间2025你那2月6日,Kura Oncology与Kyowa Kirin宣布,在研疗法ziftomenib在治疗复发/难治性(R/R)NPM1突变(NPM1-m)急性髓系白血病(AML)患者的注册性2期临床试验KOMET-001中取得积极的顶线结果。同时,Kura正按计划于2025年第二季度向美国FDA提交zifto...
百度试题 题目AML-M4Eo出现的特异的融合基因是 A. BCR-ABL B. CBFβ-MYH11 C. PML-RARα D. MLL-ENL E. IL-3-IgH 相关知识点: 试题来源: 解析 B.CBFβ-MYH11 反馈 收藏
百度试题 题目A. PML-RARα B. AML1-ETO C. PLZF-RARα D. MLL E. BCR-ABL 相关知识点: 试题来源: 解析 D 反馈 收藏
EZH2 exhibits enzymatic and non-enzymatic oncogenic activity in various cancers including MLL1-rearranged acute myeloid leukemia (MLL-r AML) and triple negative breast cancer (TNBC). Here we present MS8847, a novel VHL-recruiting EZH2 PROTAC degrader. In MLL-r AML cells, MS8847 induces ...
3506 Background: MLL gene rearrangements (MLL-r) are seen in all ages in both acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). The most common fusion partners are AF4, AF9 and ENL/ELL. Murine models suggest that the expression of MLL fusion proteins is necessary but ...